ArticleJournal of vascular surgery cases and innovative techniques2026
Postoperative outcomes of ligasure use during common femoral artery exposure.
Article in Journal of vascular surgery cases and innovative techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Seroma formation after common femoral artery (CFA) exposure is a recognized complication in vascular surgery, associated with delayed wound healing and graft-related morbidity. Reported seroma rates following CFA exposure using standard electrocautery range from 5% to 15% for cases requiring operative reintervention. The LigaSure bipolar vessel sealing system has demonstrated efficacy in sealing lymphatic channels in other surgical specialties, but its safety and impact in vascular groin surgery have not been well-characterized. We evaluated the safety, feasibility, and postoperative outcomes associated with LigaSure use during CFA exposure. Methods: We conducted a retrospective cohort study of consecutive patients undergoing open CFA exposure using LigaSure at a tertiary vascular referral center between June 2023 and November 2025, excluding any trauma cases. Demographic, clinical, operative, and postoperative outcome data were abstracted from the electronic medical record. The primary outcome was postoperative seroma formation, with clinical significance defined as the need for procedural or operative reintervention. Secondary outcomes included hematoma, surgical site infection, and fat necrosis. Observed outcome rates were descriptively compared with historically reported seroma rates after femoral artery exposure. Postoperative follow-up occurred during the index hospitalization and at scheduled outpatient visits. Results: Twenty-eight patients were included. Cardiovascular comorbidities were prevalent: hypertension (86%), hyperlipidemia (75%), and diabetes (50%). Four patients (14.3%; 95% confidence interval [CI], 4.03%-32.67%) developed postoperative fluid collections: two seromas (7.1%; 95% CI, 0.88%-23.50%) and two hematomas (7.1%; 95% CI, 0.88%-23.50%), comparable with historically reported seroma rates of 5% to 15% after standard electrocautery. Critically, no patients required procedural drainage, operative reintervention, or graft excision, and no graft infections or fat necrosis were observed. Only one case of skin infection and one case of skin necrosis were noted. All fluid collections resolved with conservative management, yielding a final rate of 0% for seroma requiring operative reintervention. Conclusions: LigaSure use during CFA exposure was safe and feasible, with postoperative seroma rates comparable with those historically reported for standard electrocautery. Notably, 0% of seromas required procedural or operative reintervention, an important clinical consideration given the morbidity often associated with groin seromas in vascular surgery. Although a decrease in seroma incidence was not observed relative to historical benchmarks, the favorable safety profile and absence of clinically significant lymphatic complications requiring operative reintervention support LigaSure as a reliable adjunct for groin dissection. Larger prospective comparative studies are needed to further define its impact on clinically meaningful groin wound outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.